ABSTRACT Monocarboxylate transporters (MCTs) are vital for intracellular pH homeostasis by
cancer to treat from patient's diagnosis to death 3 . Its variable natural history and clinical behaviour, recently dissected by gene-expression profiling studies 4 , endorse major concerns in the care of UBC patients, and embody a substantial economic burden in health care systems. In fact, the group of low grade non-muscle invasive (NMI) UBC patients suffers from high recurrence rates. Moreover, occurrence of progression in the group of high grade NMI UBC is a frequent event. Additionally, inherent or acquired chemo-refractoriness occurs in half of the patients with muscleinvasive (MI) disseminated disease 1, [5] [6] [7] . Hence, the undeniable diagnostic and prognostic value of the conventional clinicopathological parameters 8 would certainly be refined if standardized prognostic and predictive biomarkers are included in the pathology reports.
Reprogramming of the cellular energetics, with adoption of the Warburg effect, has been recently included in the hallmarks of cancer 9 . Increased glucose metabolism 10, 11 and lactate production 12 was associated with a dismal outcome for bladder cancer patients, corroborating the use of FDG-PET (fluoro-deoxy-glucose positron emission tomography) scan as an efficient diagnostic tool 13, 14 . Despite this, the preponderance of monocarboxylate transporters (MCTs), the gateways for the efflux of lactate from highly glycolytic cells, has just begun to be unravelled in the setting of bladder cancer.
MCTs belong to the SLC16 gene family and comprise fourteen members. The membrane-bound proton-coupled isoforms MCT1 and MCT4 are the best characterized MCTs in human tissue; they transport monocarboxylates, namely lactate, through the plasma membrane, with MCT1 having an ubiquitous distribution, and MCT4 being present in highly glycolytic tissues 15 . For their proper expression at 5 the plasma membrane, MCTs require association with the cell surface glycoprotein CD147 16 . Hypoxia seems to be a main trigger mechanism of the hyper-glycolytic phenotype, leading to the upregulation of pH regulators, such as carbonic anhydrase IX (CAIX) and MCTs, to assure intracellular pH balance 17, 18 . MCTs overexpression has been described in several malignant contexts, associating with poor clinicopathological and survival parameters (reviewed in 19 
RESULTS

Clinicopathological Parameters
Occurrence of lymphovascular invasion and/or loco-regional metastases was preponderant in pT3/pT4 (p<0.001) and poorly differentiated (p=0.004 and p<0.001, respectively) cases. The 5-year disease-free survival (DFS) and overall survival (OS) rates were significantly influenced by T stage (p<0.001), grade of differentiation and type of lesion (p<0.001), occurrence of lymphovascular invasion (p=0.002 and p<0.001, respectively) and occurrence of loco-regional metastasis (p=0.002 and p<0.001, respectively) (data not shown).
Biological Parameters -Immunoexpression and Associations MCT1 and MCT4 were expressed in normoxic tumour regions of 35.1% (n=39) and 64.9% (n=72) UBC tissue samples, respectively. A significant decrease was noted towards positivity in hypoxic areas: only 9.0% (n=10) and 24.3% (n=27) of the samples expressed MCT1 and MCT4 in those tumour regions, respectively (p<0.001) ( Table 1 ). The same associations were observed regarding MCT4 immunoexpression in the hypoxic tumour regions, in the tumour stroma and in the blood vessels (Table 2) . CAIX expression in the hypoxic tumour regions was mainly observed in high-grade NMI papillary and MI tissue sections (p=0.016) ( Table 4) . Presence of this biomarker in normoxic zones significantly associated with a lower 5-year DFS rate (p=0.049, Figure   3D ).
Multivariate Analysis
In univariate analysis, pathological stage, grade and type of lesion, lymphovascular invasion and loco-regional metastasis were variables reaching statistical significance Sonveaux and colleagues 31 , using preclinical models of lung, cervical and colorectal cancer, described that hypoxic tumour cells produce lactate, which is exported through MCT4, diffusing to aerobic tumour cells that will internalize it through MCT1, being oxidized for energy production. These biomarkers of metabolic compartmentalization hold promise for the clinics, and a better understanding of the recently described metabolic symbioses within the tumour ecosystem will surely impact the outcome of cancer patients.
Altered cellular metabolism, as for other types of cancer, is an intrinsic hallmark of bladder cancer progression 48 . However, UBC metabolism has been described based on a homogeneous approach. In the present study, we used a cohort of 111 UBC tissue Finally, we assessed, in our UBC cohort, the tissue distribution of CAIX, a membrane-bound catalyst that traps extracellular acid by hydration of cell-generated carbon dioxide to bicarbonate and protons, controlling acidification of the tumoural extracellular pH under hypoxic conditions 69 . We observed that, although homogeneously distributed through normoxic and hypoxic tumour compartments, intensity of membrane definition was consistently higher under hypoxic conditions, which denotes increased activity of this catalyst in those tumour niches, as expected.
Moreover, CAIX positivity was mainly present in hypoxic regions of high-grade nonmuscle invasive papillary and muscle invasive tumors. Correlation of CAIX expression with parameters of UBC aggressiveness has also been reported by others, being inclusively identified as an independent prognostic factor 70, 71 . Intriguingly, plasma membrane expression of CAIX was also observed in normoxic tumour regions, as previously mentioned, which was associated with a lower 5-year disease-free survival rate. In the vast majority of the cases, the tumour stroma and the blood vessels were also stained. Probably, these interesting results reflect ongoing metabolic adaptations where "pseudo-hypoxic" regions coexist with normoxic, hypoxic and necrotic fractions of the tumour microenvironment. In fact, it has been reported that the tumor blood vessels in highly metastatic malignancies are themselves exposed to hypoxia, as indicated by pimidazole staining, due to vessel immaturity and less pericyte coverage 72 .
In 4 groups), lymphovascular invasion and loco-regional metastases (see Table 1 for example).
Forty-one (36.9%) patients were submitted to TUR with curative intention; of these, twenty-one patients underwent RC following disease recurrence and progression, or when multiple carcinoma in situ (CIS) lesions were present in the pathological specimen. Seventy (63.1%) patients had RC as their first treatment.
Platinum-based chemotherapy regimens were administered to thirty-one (27.9%) patients (neoadjuvant: 6, adjuvant: 9, palliative: 16). Mean and median follow-up were 50.9 and 37.6 months (range 1-154), respectively. The reappearance of UBC (locoregional dissemination or distant metastasis) more than 3 months after TUR/RC defined recurrence; this occurred in seventy-three (65.8%) patients. Disease-free survival (DFS) was defined as the time from the TUR/RC until recurrence. Overall 
Statistical analysis
The analysis of the immunohistochemistry results was conducted using the Statistical Package for Social Sciences (SPSS) software for Windows, version 18.0.
Associations among biomarkers' immunoexpression and clinicopathological parameters were examined for statistical significance using Pearson's chi-square (  2 ) test and Fisher's exact test (when n<5). Kaplan-Meier curves were used to evaluate five-year DFS and OS rates, being the differences analysed by Log-Rank or Breslow tests. p values lower than 0.05 were considered significant. Multivariate analysis using
Cox proportional hazards analysis was performed with variables that achieved statistical significance in the univariate analysis. LG, low grade; LVI, lymphovascular invasion; HG, high grade MI, muscle invasive; NMI, non-muscle invasive; NMIP, non-muscle invasive papillary; UC-urothelial carcinoma. LG, low grade; LVI, lymphovascular invasion; HG, high grade MI, muscle invasive; NMI, non-muscle invasive; NMIP, non-muscle invasive papillary; UC-urothelial carcinoma. LG, low grade; LVI, lymphovascular invasion; HG, high grade MI, muscle invasive; NMI, non-muscle invasive; NMIP, non-muscle invasive papillary; UC-urothelial carcinoma. 
